Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent Advances in Medical Therapy for Urological Cancers.
Yuasa T, Urasaki T, Oki R. Yuasa T, et al. Among authors: oki r. Front Oncol. 2022 Apr 4;12:746922. doi: 10.3389/fonc.2022.746922. eCollection 2022. Front Oncol. 2022. PMID: 35444946 Free PMC article. Review.
Post-Systemic Chemotherapy Prognoses of Recurrent/Metastatic Soft Tissue Sarcoma Patients with Retroperitoneal/Intra-Abdominal Origin versus Those with Extremities/Trunk Origin.
Nakano K, Fukuda N, Sato Y, Urasaki T, Ohmoto A, Wang X, Hayashi N, Suto H, Udagawa S, Oki R, Yunokawa M, Ono M, Tomomatsu J, Minami Y, Hayakawa K, Tanizawa T, Ae K, Matsumoto S, Takahashi S. Nakano K, et al. Among authors: oki r. Oncology. 2022;100(4):238-246. doi: 10.1159/000522303. Epub 2022 Jan 31. Oncology. 2022. PMID: 35100601
The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
Oka S, Inoshita N, Miura Y, Oki R, Miyama Y, Nagamoto S, Ogawa K, Sakaguchi K, Kondoh C, Kurosawa K, Urakami S, Takano T, Okaneya T. Oka S, et al. Among authors: oki r. Urol Oncol. 2018 Aug;36(8):365.e9-365.e14. doi: 10.1016/j.urolonc.2018.04.015. Epub 2018 May 28. Urol Oncol. 2018. PMID: 29853346
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, Sakaguchi S, Nokihara H, Kanai K, Tsunemi T, Hattori N, Hatanaka Y, Sonoo M, Atsuta N, Sobue G, Shimizu T, Shibuya K, Ikeda K, Kano O, Nishinaka K, Kojima Y, Oda M, Komai K, Kikuchi H, Kohara N, Urushitani M, Nakayama Y, Ito H, Nagai M, Nishiyama K, Kuzume D, Shimohama S, Shimohata T, Abe K, Ishihara T, Onodera O, Isose S, Araki N, Morita M, Noda K, Toda T, Maruyama H, Furuya H, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Oki R, et al. JAMA Neurol. 2022 Jun 1;79(6):575-583. doi: 10.1001/jamaneurol.2022.0901. JAMA Neurol. 2022. PMID: 35532908 Free PMC article. Clinical Trial.
73 results